Veterinary Drugs for Cattle Butaphosphan +Vb12 Injection Nutrition Injection Veterinary Medicine 100ml

Name: Veterinary Drugs for Cattle Butaphosphan +Vb12 Injection Nutrition Injection Veterinary Medicine 100ml
Brand: Jiangxi Bolai Pharmacy Co., Ltd.
SKU: 1913762665

Jiangxi, ChinaJiangxi Bolai Pharmacy Co., Ltd.

US$1.50

3,000 Pieces

Sample price:US$0.00/piece.Request sample

Product profile

Customization

Available

Varieties

General Disease Prevention Medicine

Component

Chemical Synthetic Drugs

Model NO.

100ml

Type

The First Class

Pharmacodynamic Influential Factors

Incompatibility

Storage Method

Prevent High or LowTemperature

Veterinary Reg. No.

Certificate

GMP, COA, FSC

Lead Time

30 Days

Deposit

50%

Package

Design Per Your Request

Transport Package

Glass Bottle

Specification

100ml

Trademark

BOLAI

Origin

China

HS Code

3004909099

Production Capacity

1000000 Per Month

Company profile

Jiangxi Bolai Pharmacy Co., Ltd.

Jiangxi, China

CertifiedBusiness Type: Manufacturer/Factory CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2010-02-01 CertifiedNearest Port: Shanghai Port, Guangzhou Port, Jiujiang PortAverage Response Time: ≤8.27h CertifiedTerms of Payment: LC, T/T, D/P, etc.

AI-Powered supplier vetting

SummaryJiangxi Bolai Pharmacy Co., Ltd. is identified as a Chinese manufacturer of veterinary medicines, feed additives, and related animal-health products. The supplier reports a 45,000 m² manufacturing plant, more than 10 production lines, 17 GMP-certified automatic production lines, 27 dosage-form products, and stated high output for several products. It serves domestic and multiple overseas markets, offers FOB/CIF/CFR quotation terms, and reports lead times of within 15 working days off-season and one month during peak season. Evidence indicates R&D infrastructure, technical services, registration dossier and sample support, and a quality-control team of 11–20 staff. However, the provided slices do not establish specific customer cases, after-sales procedures, complete management-system certifications, or sufficient financial information for firm assessment.

Supplier typeThe supplier is explicitly identified as a factory and manufacturer in China, with a stated focus on veterinary medicines, feed additives, agricultural industrialization, R&D, production, marketing, and technical services. This directly supports classification as a manufacturing supplier.

CertificationsThe supplier states that it operates 17 GMP-certified automatic production lines and describes its facility as a GMP factory. However, the specific certification listed for supplier management systems is only “Others,” and no complete certification scope or certificate details are provided.

After-Sales capabilityThe supplier states that it provides technical services and can support customer registration dossiers and samples. These statements show some customer-support capability, but the slices do not describe warranty handling, complaint response, maintenance, or formal after-sales procedures.

R&D capabilityThe supplier reports a post-doctoral scientific research workstation, membership in a Chinese veterinary chemical industry technology innovation alliance, R&D activity, and seven years of R&D engineer experience. These are direct indicators of established research capability and product development support.

Production capacityProduction capability is strongly supported by the 45,000 m² plant, more than 10 production lines, 17 GMP-certified automatic lines, 27 dosage forms, reported output for ivermectin and oxytetracycline injections and feed additives, and stated peak/off-peak lead times. The supplier also reports broad veterinary and feed-product coverage.

Customization capabilityThe supplier offers multiple dosage forms and product categories, including injections, oral solutions, powders, premixes, granules, coated essential oils, disinfectants, and feed additives, and supports registration dossiers and samples. This indicates product-format flexibility, although bespoke formulation or private-label customization is not explicitly confirmed.